- Processing Solutions
- Agitators
- Asset Management
- Automation
- Blowers & Fans
- Centrifuges
- Chillers
- Compressors
- Conveyors
- Dryers & Evaporators
- Feeders
- Filtration & Separation
- Flowmeters
- Fluid Flow
- Heat Exchangers
- Instrumentation
- Level Measurement
- Maintenance & Safety
- Mixing & Blending
- Motors & Drives
- Oil Skimmers
- Piping & Tubing
- Packaging Equipment
- Powder & Bulk Solids
- Process Control
- Pumps & Seals
- Size Reduction
- Tanks & Vessels
- Valves & Actuators
- Weighing
- More
- Newsletters
- White Papers
- Buyer's Guide
- Videos
- Events
- Advertise
More
Affymax, Inc. today announced that it has
received a $10 million development milestone payment from Takeda Pharmaceutical
Company as part of the companies’ exclusive global agreement to develop and
commercialize peginesatide (formerly known as Hematide™), Affymax’s investigational drug for the
treatment of anemia in chronic renal failure patients, according to a press
release. The payments were triggered by the acceptance and filing of the New
Drug Application for peginesatide by the FDA. If approved, peginesatide will be
the first once-monthly erythropoiesis stimulating agent (ESA) available for the
treatment of anemia associated with CKD patients on dialysis in the United
States.
